ABT 925 Fumerate - CAS 220519-07-3
Catalog number: 220519-07-3
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C24H31F3N6O5S
Molecular Weight:
572.604
COA:
Inquire
Targets:
Dopamine Receptor
Description:
A 437203 is a selective dopamine (DA) D3 receptor antagonist suited to evaluate the physiological role(s) of D3 receptors. A 437203 shows an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors.
Purity:
>98%
Appearance:
Solid powder
Synonyms:
(E)-but-2-enedioic acid;2-[3-[4-[2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]propylsulfanyl]-1H-pyrimidin-6-one; UNII-DMH23OL273; 220519-07-3 (anhydrous); 220519-06-2 (anhydrous free base); ABT-925 anhydrous
MSDS:
Inquire
InChIKey:
KQMGYGQUUXCWBL-WLHGVMLRSA-N
InChI:
1S/C20H27F3N6OS.C4H4O4/c1-19(2,3)17-25-14(20(21,22)23)13-15(26-17)29-10-8-28(9-11-29)7-4-12-31-18-24-6-5-16(30)27-18;5-3(6)1-2-4(7)8/h5-6,13H,4,7-12H2,1-3H3,(H,24,27,30);1-2H,(H,5,6)(H,7,8)/b;2-1+
Canonical SMILES:
CC(C)(C)C1=NC(=CC(=N1)N2CCN(CC2)CCCSC3=NC=CC(=O)N3)C(F)(F)F.C(=CC(=O)O)C(=O)O
1.Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.
Gross G;Wicke K;Drescher KU Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):155-66. doi: 10.1007/s00210-012-0806-3. Epub 2012 Nov 6.
The potential of D(3) receptor antagonism to treat positive, negative, and cognitive symptoms of schizophrenia is reviewed on the basis of preclinical results and preliminary clinical data. Dopamine D(3) receptors are expressed in mesencephalic, limbic, and cortical areas relevant to psychotic and cognitive symptoms of schizophrenia. As expected, selective dopamine D(3) receptor antagonists are not effective in antipsychotic animal models, reflecting D(2) receptor antagonism. However, selective D(3) receptor antagonists affect electrical activity of dopamine neurons in the ventral tegmental area similar to atypical antipsychotics, counteract effects produced by NMDA glutamate receptor blockade, and enhance cortical dopamine and acetylcholine in microdialysis. In contrast to dopamine D(2) receptor antagonists, D(3) antagonists positively influence a variety of social and cognitive behaviors in rodents, including tests representing cognitive flexibility and executive function, which are both impaired in schizophrenia patients. Despite considerable affinity for D(3) receptors, the second-generation antipsychotics clozapine, risperidone, and olanzapine when administered to patients with schizophrenia seem not to occupy D(3) receptors sufficiently to derive any conclusion on a D(3)-mediated therapeutic benefit.
2.Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925.
Graff-Guerrero A;Redden L;Abi-Saab W;Katz DA;Houle S;Barsoum P;Bhathena A;Palaparthy R;Saltarelli MD;Kapur S Int J Neuropsychopharmacol. 2010 Apr;13(3):273-87. doi: 10.1017/S1461145709990642. Epub 2009 Sep 15.
Dopamine D3 receptors are preferentially localized in the limbic system and midbrain, and thus may be involved in the pathophysiology of neuropsychiatry disorders. [11C](+)-PHNO is the first preferential D3 receptor radioligand in humans, yet there are no blockade studies with a D3 receptor antagonist in humans. This study characterized the blockade of [11C](+)-PHNO binding by ABT-925, a D3 receptor antagonist, in healthy male subjects. Sixteen subjects underwent 2-3 positron emission tomography (PET) scans, at baseline and following one or two doses of ABT-925 ranging from 50 mg to 600 mg. Receptor occupancies were estimated for globus pallidus, substantia nigra, caudate, putamen, and ventral striatum. At the 600-mg dose (n=9), ABT-925 receptor occupancy (mean+/-s.d.) was higher in substantia nigra (75+/-10%) and globus pallidus (64+/-22%) than in ventral striatum (44+/-17%), caudate (40+/-18%) and putamen (38+/-17%) (ANOVA: F4,140=15.02, p<0.001). The fractions of [11C](+)-PHNO binding attributable to D3 receptors in D3 receptor-rich regions were 100% (substantia nigra) and 90% (globus pallidus), and in D2 receptor-rich regions were 55% (caudate) and 53% (putamen). The ED50 of ABT-925 was 4.
3.Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response.
Bhathena A;Wang Y;Kraft JB;Idler KB;Abel SJ;Holley-Shanks RR;Robieson WZ;Spear B;Redden L;Katz DA Transl Psychiatry. 2013 Apr 9;3:e245. doi: 10.1038/tp.2013.22.
ABT-925, a selective dopamine D3 receptor (DRD3) antagonist, was tested in schizophrenia. A DRD3 gene polymorphism results in an S9G amino-acid change that has been associated with lower risk of schizophrenia, higher affinity for dopamine and some antipsychotics, and differential response to some antipsychotics. The effect of S9G genotype on response to ABT-925 was examined. DNA samples (N=117) were collected in a proof-of-concept, double-blind, randomized, placebo-controlled study of ABT-925 (50 or 150 mg QD) in acute exacerbation of schizophrenia. A pre-specified analysis assessed impact of genotype (SS versus SG+GG) on change from baseline to final evaluation for the Positive and Negative Syndrome Scale (PANSS) total score using analysis of covariance with genotype, treatment and genotype-by-treatment interaction as factors, and baseline score as covariate. Significant genotype-by-treatment interaction (P=0.015) was observed for change from baseline to final evaluation for the PANSS total score. Within subgroup analyses showed significant improvement from placebo in the SG+GG group treated with ABT-925 150 mg. More favorable clinical outcomes were observed in patients treated with ABT-925 150 mg who carried the DRD3 G allele than in those who carried the DRD3 SS genotype.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Dopamine Receptor Products


CAS 125572-93-2 Rotigotine Hydrochloride

Rotigotine Hydrochloride
(CAS: 125572-93-2)

The hydrochloride salt form of Rotigotine which is a dopamine D2 and D3 receptor agonist and has been shown to be effective in the treatment of Parkinson's dise...

CAS 913611-97-9 Brexpiprazole

Brexpiprazole
(CAS: 913611-97-9)

Brexpiprazole, a novel atypical antipsychotic drug, is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). It is approved for the...

CAS 85378-82-1 (+)-AJ 76 hydrochloride

(+)-AJ 76 hydrochloride
(CAS: 85378-82-1)

The hydrochloride salt form of (+)-AJ 76, which is a dopamine receptor antagonist.

Amitifadine hydrochloride
(CAS: 410074-74-7)

A Serotonin-Preferring Triple Reuptake Inhibitor for the Treatment of Major Depression, with the IC50 values for serotonin, norepinephrine and dopamine reuptake...

CAS 96850-13-4 Indatraline hydrochloride

Indatraline hydrochloride
(CAS: 96850-13-4)

Indatraline hydrochloride is the hydrobromide salt of indatraline, which is a potent monoamine uptake inhibitor. It inhibits the synaptosomal uptake of noradren...

CAS 93601-85-5 (R)-5-Methoxy-N-propyl-2-aminotetraline hydrochloride

(R)-5-Methoxy-N-propyl-2-aminotetraline
(CAS: 93601-85-5)

(R)-5-Methoxy-N-propyl-2-Aminotetraline hydrochloride is a dopamine receptor agonist and an intermediate in the production of antipsychotic agents and antiparki...

CAS 57202-76-3 6-Methyl Pergolide

6-Methyl Pergolide
(CAS: 57202-76-3)

6-Methyl Pergolide is a dopamine agonist. It is also a potent antagonist of 5-HT2A and 5-HT2B receptors on porcine cardiac valves. It increases serum corticoste...

CAS 182210-74-8 (S)-5-Hydroxy-DPAT hydrobromide

(S)-5-Hydroxy-DPAT hydrobromide
(CAS: 182210-74-8)

A potent and selective dopamine (DA) D2 receptor agonist.

Quick Inquiry

Verification code

Featured Items